Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hita Moudgalya"'
Autor:
Philip Bonomi, Hita Moudgalya, Sandra L. Gomez, Palmi Shah, Sanjib Basu, Marta Batus, Levi B. Martinka, Ahmed Abdelkader, Iphigenia Tzameli, Sonia Cobain, Susie Collins, Edmund J. Keliher, Danna M. Breen, Roberto A. Calle, Mary Jo Fidler, Jeffrey A. Borgia
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 6, Pp 2311-2322 (2024)
Abstract Background The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment‐naïve, advanced non‐small cell lung cance
Externí odkaz:
https://doaj.org/article/9783cab46df946fea677b29c1671a54e
Autor:
Cristina L, Fhied, Imad, Tarhoni, David, Gerard, Grant M, Lewin, Hita, Moudgalya, Jeffrey R, Schneider, Jeffrey A, Borgia
Publikováno v:
Journal of Visualized Experiments.
Multiplex technologies for interrogating multiple biomarkers in concert have existed for several decades; however, methods to evaluate multiple epitopes on the same analyte remain limited. This report describes the development and optimization of a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111d769f112602f7dd9b4e50e6d313ee
https://doi.org/10.3791/63352-v
https://doi.org/10.3791/63352-v
Autor:
Alexander W. Pohlman, Hita Moudgalya, Lia Jordano, Gabriela C. Lobato, David Gerard, Michael J. Liptay, Christopher W. Seder, Jeffrey A. Borgia
Publikováno v:
Oncotarget. 13
Detection rates of early-stage lung cancer are traditionally low, which contributes to inconsistent treatment responses and high rates of annual cancer deaths. Currently, low-dose computed tomography (LDCT) screening produces a high false discovery r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea116672d387b24db70b928622df55
https://pubmed.ncbi.nlm.nih.gov/35198099
https://pubmed.ncbi.nlm.nih.gov/35198099
Autor:
Alexander W. Pohlman, Hita Moudgalya, Lia Jordano, Gabriela C. Lobato, David Gerard, Michael J. Liptay, Christopher W. Seder, JEFFREY A BORGIA
Background: Detection rates of early-stage lung cancer are traditionally low, which contributes to inconsistent treatment responses and the highest rates of annual cancer deaths in the U.S. Currently, age and smoking history are the primary factors t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23a1fb8a26d626791f0cdad4c3817471
https://doi.org/10.21203/rs.3.rs-952465/v1
https://doi.org/10.21203/rs.3.rs-952465/v1
Autor:
Mary Jo J. Fidler, Palmi Shah, Hita Moudgalya, Marta Batus, Jeffrey Allen Borgia, Philip D. Bonomi
Publikováno v:
Journal of Clinical Oncology. 40:e24080-e24080
e24080 Background: Significantly longer OS has been reported in advanced NSCLC pts. who gained weight or maintained (skeletal muscle mass) SMI during treatment with platinum containing chemotherapy. None of these studies evaluated the relationship be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::523905cc3fe53766b937bf0c7cab9b48
https://doi.org/10.1200/jco.2022.40.16_suppl.e24080
https://doi.org/10.1200/jco.2022.40.16_suppl.e24080
Autor:
Christopher W. Seder, Hita Moudgalya, Andrew E. Donaldson, Kayla Viets Layng, Elizabeth Mauer, Janakiraman Subramanian, Cristina L. Fhied, Nicole Geissen, Gillian Alex, Justin Karush, Michael J. Liptay, Jeffrey Allen Borgia
Publikováno v:
Journal of Clinical Oncology. 40:8543-8543
8543 Background: Patients with early stage, non-small cell lung cancer (NSCLC) with solitary pulmonary lesions ≤4 cm typically have favorable outcomes. However, disease recurrence impacts up to 30% of patients, leading to either additional surgical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd7f8a8025ec4537ac2f0e2572f5a41f
https://doi.org/10.1200/jco.2022.40.16_suppl.8543
https://doi.org/10.1200/jco.2022.40.16_suppl.8543
Autor:
Marta Batus, Sanjib Basu, Hita Moudgalya, Jeffrey A. Borgia, Wen Rong Lie, Imad Tarhoni, Mary J. Fidler, Philip Bonomi, Danielle Pepin
Publikováno v:
Cancer Research. 81:1621-1621
Introduction: Immune checkpoint inhibitor (ICI) therapy has shown remarkable benefits in treating non-small-cell lung cancer (NSCLC). However, progress beyond PD-L1 expression has not yielded biomarkers that can better select responders to ICI. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f532acd14f304bb2a24f9a92252a003
https://doi.org/10.1158/1538-7445.am2021-1621
https://doi.org/10.1158/1538-7445.am2021-1621
Autor:
Revathi Kollipara, Mary J. Fidler, Sanjib Basu, Marta Batus, Philip Bonomi, Megan Randall, Jeffrey A. Borgia, Hita Moudgalya
Publikováno v:
Journal of Clinical Oncology. 39:e21189-e21189
e21189 Background: Several parameters that have been associated with outcomes in patients with metastatic NSCLC treated with anti-PD1/PDL1 mAbs include tumor PD-L1 expression, tumor mutational burden, and baseline NLR. Further investigation into clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18789af3c2fb6fa35f6dfd9bf5126fe8
https://doi.org/10.1200/jco.2021.39.15_suppl.e21189
https://doi.org/10.1200/jco.2021.39.15_suppl.e21189